Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)

August 16, 2021 06:50 AM EDT

As US review of Eli Lilly-partnered PD-1 gets underway, Innovent touts another frontline win in China

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?